Ischemic Heart Disease
... ethnic minorities than in Caucasian, non-Hispanic men. As a result, the recommendations are less clearly applicable to these groups. CAC NOT recommended for asymptomatic patients with low or high ten-year CHD risk as established by the Framingham and modified Framingham/ATP risk scores. For asymptom ...
... ethnic minorities than in Caucasian, non-Hispanic men. As a result, the recommendations are less clearly applicable to these groups. CAC NOT recommended for asymptomatic patients with low or high ten-year CHD risk as established by the Framingham and modified Framingham/ATP risk scores. For asymptom ...
Introduction - Fullfrontalanatomy.com
... The pericardium is the serous membrane lining the pericardial cavity, which surrounds the heart Visceral pericardium (epicardium) covers the heart’s outer surface Parietal pericardium lines the inner surface of the pericardial sac ...
... The pericardium is the serous membrane lining the pericardial cavity, which surrounds the heart Visceral pericardium (epicardium) covers the heart’s outer surface Parietal pericardium lines the inner surface of the pericardial sac ...
Exercise_in_high_risk3
... ventricular fibrillation (VF). In heart failure, sympathetic stimulation,lead to spontaneous Ca++ release and enhanced Na-Ca exchange, together with IK1 reduction, results in greater propensity for developing delayed after-depolarization. In Hypertrophic cardiomyopathy, heterogeneous substrate may b ...
... ventricular fibrillation (VF). In heart failure, sympathetic stimulation,lead to spontaneous Ca++ release and enhanced Na-Ca exchange, together with IK1 reduction, results in greater propensity for developing delayed after-depolarization. In Hypertrophic cardiomyopathy, heterogeneous substrate may b ...
ICDs: What We Have Learned and Current Guidelines
... ICD therapy is indicated in patients who are survivors of cardiac arrest due to ventricular fibrillation or hemodynamically unstable sustained VT after evaluation to define the cause of the event and to exclude any completely reversible causes. ICD therapy is indicated in patients with structural he ...
... ICD therapy is indicated in patients who are survivors of cardiac arrest due to ventricular fibrillation or hemodynamically unstable sustained VT after evaluation to define the cause of the event and to exclude any completely reversible causes. ICD therapy is indicated in patients with structural he ...
Surgical Remodeling of the Left Ventricle in Heart Failure
... reduce ventricular volume in patients with end-stage dilated cardiomyopathy with ejection fractions < 20%.10) In this operation, a wedge of LV muscle between the papillary muscles is resected from apex to mitral annulus. If papillary muscles are resected (extended procedure), the mitral valve is rep ...
... reduce ventricular volume in patients with end-stage dilated cardiomyopathy with ejection fractions < 20%.10) In this operation, a wedge of LV muscle between the papillary muscles is resected from apex to mitral annulus. If papillary muscles are resected (extended procedure), the mitral valve is rep ...
Clinical Application of the HF Diagnostic Trends
... or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction less than or equal to 35% and a prolonged QRS duration. Indications for Virtuoso: Virtuoso DR/VR devices are indicated to provide ventricular antitachycardia pacing ...
... or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction less than or equal to 35% and a prolonged QRS duration. Indications for Virtuoso: Virtuoso DR/VR devices are indicated to provide ventricular antitachycardia pacing ...
Measure #198: Heart Failure: Left Ventricular Ejection Fraction
... Evaluation of LVEF in patients with heart failure provides important information that is required to appropriately direct treatment. Several pharmacologic therapies have demonstrated efficacy in slowing disease progression and improving outcomes in patients with left ventricular systolic dysfunction ...
... Evaluation of LVEF in patients with heart failure provides important information that is required to appropriately direct treatment. Several pharmacologic therapies have demonstrated efficacy in slowing disease progression and improving outcomes in patients with left ventricular systolic dysfunction ...
Measuring cardiac efficiency: is it clinically useful?
... patients with various cardiac diseases, what was the cardiac efficiency of your patient, and how treatment could possibly favorably change the cardiac efficiency of this patient? I, certainly, never considered this consciously, and I doubt that many of us do. Nevertheless, the concept of cardiac eff ...
... patients with various cardiac diseases, what was the cardiac efficiency of your patient, and how treatment could possibly favorably change the cardiac efficiency of this patient? I, certainly, never considered this consciously, and I doubt that many of us do. Nevertheless, the concept of cardiac eff ...
Heart and Heart Diseases
... 1. Coronary artery disease • Caused by atherosclerosis (plague) • May cause chest pain (angina) • A ruptured plaque can cause unstable angina or a heart attack • Complications: cardiac arrest, ventricular rupture • Risk factors: Obesity, high blood pressure, uncontrolled diabetes, smoking and high ...
... 1. Coronary artery disease • Caused by atherosclerosis (plague) • May cause chest pain (angina) • A ruptured plaque can cause unstable angina or a heart attack • Complications: cardiac arrest, ventricular rupture • Risk factors: Obesity, high blood pressure, uncontrolled diabetes, smoking and high ...
REPORT ON ESC 2012 Anthony J Dalby, Cardiologist, Milpark
... A symposium was held on anticoagulation in AF. In patients with AF, hospitalisation has constituted 52% of the cost with drugs making up only 23%. Trials have shown that warfarin reduces stroke rat ...
... A symposium was held on anticoagulation in AF. In patients with AF, hospitalisation has constituted 52% of the cost with drugs making up only 23%. Trials have shown that warfarin reduces stroke rat ...
Post-Operative Hypertension
... Uncontrolled Post-op hypertension is an independent predictor of morbidity and mortality, more unplanned ICU admissions and greater mortality. Left untreated, will depress LV performance, increased myocardial O2 demand, CVA, acute MI, arrhythmias, suture line disruption and bleeding. Pathophysiology ...
... Uncontrolled Post-op hypertension is an independent predictor of morbidity and mortality, more unplanned ICU admissions and greater mortality. Left untreated, will depress LV performance, increased myocardial O2 demand, CVA, acute MI, arrhythmias, suture line disruption and bleeding. Pathophysiology ...
Hypertension Systolic ≥140 or Diastolic ≥ 90 Stage I systolic=140
... Palpitations, fatigue or poor exercise tolerance, mild dyspnea, presyncope. Less common symptoms o Angina, profound dyspnea, or syncope. o Tachycardia may or may not be present, depending on the degree of AV block associated with the atrial flutter activity The heart rate is often approximatel ...
... Palpitations, fatigue or poor exercise tolerance, mild dyspnea, presyncope. Less common symptoms o Angina, profound dyspnea, or syncope. o Tachycardia may or may not be present, depending on the degree of AV block associated with the atrial flutter activity The heart rate is often approximatel ...
Men with Poor Left Ventricular Function Have Lower Levels of
... PJ PUGH, KM ENGLISH, TH JONES and KS CHANNER Department of Cardiology, Royal Hallamshire Hospital, Sheffield, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Background: Low androgen levels in men are associated with risk factors for acute myocardial infarction (AMI ...
... PJ PUGH, KM ENGLISH, TH JONES and KS CHANNER Department of Cardiology, Royal Hallamshire Hospital, Sheffield, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Background: Low androgen levels in men are associated with risk factors for acute myocardial infarction (AMI ...
Final Protocol - Medical Services Advisory Committee
... Dynamics2 have developed a cardiac contractility modulation (CCM) device for this group of patients. Impulse Dynamics are seeking the MBS listing of CCM therapy for the following patient population: o ...
... Dynamics2 have developed a cardiac contractility modulation (CCM) device for this group of patients. Impulse Dynamics are seeking the MBS listing of CCM therapy for the following patient population: o ...
heart failure
... inhibitors (e.g., milrinone, venarinone) :excess mortality Intermittent intravenous inotropic agent may be of value in improving the quality of life or as a bridge to cardiac transplantation. Catecholamine infusions have been associated with excess mortality. Cardiac transplantation, left vent ...
... inhibitors (e.g., milrinone, venarinone) :excess mortality Intermittent intravenous inotropic agent may be of value in improving the quality of life or as a bridge to cardiac transplantation. Catecholamine infusions have been associated with excess mortality. Cardiac transplantation, left vent ...
Reverse Remodeling: Does This Work?
... inhibitors (ACEIs) – signs of pathological reversibility were demonstrated. In these cases clinical improvement appeared on a medium term, even in the condition of stopping the mechanical support. Thus, the concept of reverse remodeling developed. The term was introduced by Kass in 1995 and revised ...
... inhibitors (ACEIs) – signs of pathological reversibility were demonstrated. In these cases clinical improvement appeared on a medium term, even in the condition of stopping the mechanical support. Thus, the concept of reverse remodeling developed. The term was introduced by Kass in 1995 and revised ...
AF_in_young_patient_-_a_serial_case_lessons
... Case report 1: a 16 year-old male came to the ER with dyspnea on exertion and palpitation since 3 days prior to admission. Paroxysmal nocturnal dyspnea and edema of extremities were also complained. There was a history of untreated pharyngitis on childhood. ECG showed atrial fibrillation with rapid ...
... Case report 1: a 16 year-old male came to the ER with dyspnea on exertion and palpitation since 3 days prior to admission. Paroxysmal nocturnal dyspnea and edema of extremities were also complained. There was a history of untreated pharyngitis on childhood. ECG showed atrial fibrillation with rapid ...
Sudden Cardiac Arrest Awareness Form
... blood to the heart. The second most common cause of sudden cardiac arrest in athletes in the United States. Aortic Valve Abnormalities – failure of the aortic (the valve between the heart and the aorta) to develop properly; usually causes a loud heart murmur. Non-Compaction Cardiomyopathy – a co ...
... blood to the heart. The second most common cause of sudden cardiac arrest in athletes in the United States. Aortic Valve Abnormalities – failure of the aortic (the valve between the heart and the aorta) to develop properly; usually causes a loud heart murmur. Non-Compaction Cardiomyopathy – a co ...
cardiac arrithmia
... • Ventricular flutter (VF) - a frequent (up to 200-300 per minute) and rhythmic excitement and their reduction. Fibrillation (flicker) ventricles (VF) - an equally frequent (up to 200-500 per minute), but random, irregular excitation and reduction of individual muscle fibers, leading to the cessati ...
... • Ventricular flutter (VF) - a frequent (up to 200-300 per minute) and rhythmic excitement and their reduction. Fibrillation (flicker) ventricles (VF) - an equally frequent (up to 200-500 per minute), but random, irregular excitation and reduction of individual muscle fibers, leading to the cessati ...
Sudden Cardiac Arrest Awareness Form
... blood to the heart. The second most common cause of sudden cardiac arrest in athletes in the United States. Aortic Valve Abnormalities – failure of the aortic (the valve between the heart and the aorta) to develop properly; usually causes a loud heart murmur. Non-Compaction Cardiomyopathy – a co ...
... blood to the heart. The second most common cause of sudden cardiac arrest in athletes in the United States. Aortic Valve Abnormalities – failure of the aortic (the valve between the heart and the aorta) to develop properly; usually causes a loud heart murmur. Non-Compaction Cardiomyopathy – a co ...
Glossary of Heart Failure Terms
... Atria: The upper chambers of the heart that pump blood to the lower chambers (ventricles). Atrial Fibrillation (AF): A very fast, disorganized heart rhythm that starts in the atria (upper chambers of the heart). Atrial Tachycardia (AT): A rapid heart rate that starts in the atria. (Includes AF, and ...
... Atria: The upper chambers of the heart that pump blood to the lower chambers (ventricles). Atrial Fibrillation (AF): A very fast, disorganized heart rhythm that starts in the atria (upper chambers of the heart). Atrial Tachycardia (AT): A rapid heart rate that starts in the atria. (Includes AF, and ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.